Antibe Therapeutics Inc(Pre-Merger) ATBPF

RE:RE:RE:RE:2021 Year End Financial Results

[RalphRalph]

Your assumptions about how Big Pharma values a pipeline/platform are misinformed.  I strongly doubt that Big Pharma cares about preclinical IP in areas that are already crowded with competition.  A company proves its platform to Big Pharma by advancing molecules through the clinic and providing validated clinical trial data - not by amassing a bunch of preclinical/discovery IP.   Hence the importance of moving 3:52 along.

 

MrMugsy wrote:

RalphRalph wrote:

Some good for sure, but there are some concerning aspects as well.  Note the P3 delay.  Also, why has 352 not progressed further?  It's perplexing that amidst all other initiatives, they've not been able to advance 352.  Before they add more preclinical IP to the pipeline (especially in crowded areas like IBD & Alzheimer's), perhaps they could focus on progressing 340/352.  A company with a bunch of preclinical IP is generally not as valuable as a similar company with validated clinical data on 2-3 molecules.  IP is only useful if you can move it forward in the clinic.

 

And still no deal re: Citagenix.  The company has definitely taken some good steps, but it would be nice to get some kind of explanation as to why long-discussed goals (Cita, 352 advancement, etc) have not been accomplished.

Forestview wrote: Financials look strong.  Good summary.  Exciting times ahead.  

GameChangerBet wrote: https://www.businesswire.com/news/home/20210628005228/en/Antibe-Therapeutics-Reports-2021-Year-End-Financial-Results-and-Business-Highlights

 

 

RalphRalph ... will try to add to your comments.  My opinion only.

I think we call all agree that things are happening very quickly now.  Some things become more important while others become less important.  Constantly in flux and likely going change even faster going forward.

For example, looks like Dan is saying Q1 2022 for the trial but he also said (at Raymond James) that he wants to start enrolling by Christmas.  I think it all means the same thing.

Also, with the Dalraiada collaboration, the biggest item there is related to "developing fresh IP for existing pipeline drugs to lengthen the duration of patents and market protection."  This seems very important to me as we're into the key negotiations with Big Pharma.  You gotta prove this to Big Pharma if you're looking for maximum payout.  Speaking of payout ... if we use the Nuance deal as a "floor" for where such a negotiation could go ... we're talking about a $944M CAD deal, with 20% paid upfront, with double digit royalty.  That's what I'd assume to be the minimum and it only goes up from there.  Then again, if you sell OTENA to Big Pharma, we really care a whole lot less about the dates going forward because we'll then be focused on other drug opportunities.

Back to trial delays.  Some will certainly consider it a delay but I understand that there may be some additional (small) studies underway right now - one being in Kansas City.  So ... maybe not delayed - just evolving.  I don't have any details but I'm just saying ... thing are changing faster IMO.

I think we all would like them to focus on what they have - but - adding to the pipeline is likely very helpful when talking with Big Pharma and trying to get more bang for our negotiating buck.  Alzheimer's might be crowded but if we have something that's much better than what's out there ... we should pursue it.

Just a few things to think about - just saying ... strap on that belt ... it's only going to get bumpier IMO.